ইঙ্গিত ও ব্যবহার
Octanine F (Recombinant), is a human blood coagulation factor indicated in adults and children ≥ 12 years of age with hemophilia B for: On-demand treatment and control of bleeding episodes Perioperative management Routine prophylaxis to reduce the frequency of bleeding episodes Octanine F is not indicated for induction of immune tolerance in patients with hemophilia B
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
For intravenous use after reconstitution only.On-demand treatment and control of bleeding episodes and perioperative management of bleeding: One international unit (IU) of coagulation factor IX per kg body weight increases the circulating activity of factor IX by 0.98 IU/dL.Initial dose: Required factor IX units (IU)= body weight (kg) x desired factor IX increase (% of normal or IU/dL) x reciprocal of observed recovery (IU/kg per IU/dL). The maintenance dose depends on the type of bleed or surgery, the intensity of the hemostatic challenge, and number of days until adequate wound healing is achieved. Pediatric Use: The safety and effectiveness of coagulation factor IX in pediatric patients below the age of 12 years have not been established. Geriatric Use: Clinical studies of coagulation factor IX did not include subjects aged 65 and over. It is not known whether elderly patients respond differently than younger patients. Individualize dose selection for elderly patients
পার্শ্বপ্রতিক্রিয়া
এই ব্র্যান্ডের পার্শ্বপ্রতিক্রিয়ার তথ্য এখনো পাওয়া যায়নি।
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Hypersensitivity reactions, including anaphylaxis has occurred. Should symptoms occur, discontinue Octanine F and administer appropriate treatment. Patients may also develop hypersensitivity to hamster (CHO) protein, which is present in trace amounts in the productDevelopment of neutralizing antibodies (inhibitors) to Octanine F may occur. If expected factor IX activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor IX inhibitor concentrationNephrotic syndrome has been reported following immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitorsThromboembolism has occurred with Octanine F use
নিষেধাজ্ঞা
Do not use in patients with known hypersensitivity to Coagulation Factor IX or its excipients, including hamster protein